Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 18, 2023

Impact of Bendamustine Treatment Before Apheresis on Outcomes in Patients With LBCL Receiving CAR T-Cell Therapy

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
J. Clin. Oncol 2023 Oct 24;[EPub Ahead of Print], G Iacoboni, V Navarro, AÁ Martín-López, K Rejeski, M Kwon, KA Jalowiec, P Amat, JL Reguera-Ortega, L Gallur, V Blumenberg, S Gutiérrez-Herrero, C Roddie, A Benzaquén, J Delgado-Serrano, MA Sánchez-Salinas, R Bailén, C Carpio, L López-Corral, R Hernani, M Bastos, M O'Reilly, L Martín-Martín, M Subklewe, P Barba

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading